Pharsight

1. List of Dyloject drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946292	JAVELIN PHARMS INC	Formulations of low dose diclofenac and beta-cyclodextrin	Mar, 2027 (4 years from now)

Market Authorisation Date: 23 December, 2014

Treatment: Management of pain

Dosage: SOLUTION;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
37.5 mg/mL, 1 mL single-dose vials	15 Dec, 2015	1	18 Jun, 2019	22 Mar, 2027	Eligible

Strength	Dosage	Availability
37.5MG/ML (37.5MG/ML)	SOLUTION;INTRAVENOUS	Discontinued

DYLOJECT family patents

United States

Korea, Republic of

Japan

European Union

Israel

China

Australia

Canada

Mexico

South Africa

Brazil

2. List of Pennsaid drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220784	HORIZON	Diclofenac topical formulation	Oct, 2027 (4 years from now)
US9132110	HORIZON	Treatment of pain with topical diclofenac	Oct, 2027 (4 years from now)
US9168305	HORIZON	Diclofenac topical formulation	Oct, 2027 (4 years from now)
US9066913	HORIZON	Diclofenac topical formulation	Oct, 2027 (4 years from now)
US9339551	HORIZON	Diclofenac topical formulation	Oct, 2027 (4 years from now)
US9339552	HORIZON	Diclofenac topical formulation	Oct, 2027 (4 years from now)
US9539335	HORIZON	Diclofenac topical formulation	Oct, 2027 (4 years from now)
US8563613	HORIZON	Diclofenac topical formulation	Oct, 2027 (4 years from now)
US8871809	HORIZON	Diclofenac topical formulation	Oct, 2027 (4 years from now)
US9101591	HORIZON	Diclofenac topical formulation	Oct, 2027 (4 years from now)
US9168304	HORIZON	Diclofenac topical formulation	Oct, 2027 (4 years from now)
US8252838	HORIZON	Diclofenac topical formulation	Apr, 2028 (5 years from now)
US9415029	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US8618164	HORIZON	Treatment of pain with topical diclofenac compounds	Jul, 2029 (6 years from now)
US9375412	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US8217078	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US8741956	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US9370501	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US8546450	HORIZON	Treatment of pain with topical diclofenac compounds	Aug, 2030 (7 years from now)

Market Authorisation Date: 16 January, 2014

Treatment: Use of topical diclofenac for treating pain; Use of topical diclofenac sodium for treating pain; Use of topical diclofenac on a joint for treating osteoarthritis; Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant

Dosage: SOLUTION;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.015	11 Jul, 2012	1	27 May, 2014	10 Jul, 2029	Eligible
0.02	03 Jun, 2014	1		09 Aug, 2030	Extinguished

Strength	Dosage	Availability
2%	SOLUTION;TOPICAL	Prescription

PENNSAID family patents

United States

China

European Union

Hong Kong

Israel

New Zealand

Australia

Denmark

Russia

Canada

Mexico

South Africa

Japan

Brazil

3. List of Pennsaid drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618164	NUVO PHARMS INC	Treatment of pain with topical diclofenac compounds	Jul, 2029 (6 years from now)
US8741956	NUVO PHARMS INC	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US8217078	NUVO PHARMS INC	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US8546450	NUVO PHARMS INC	Treatment of pain with topical diclofenac compounds	Aug, 2030 (7 years from now)

Market Authorisation Date: 04 November, 2009

Treatment: Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Use of topical diclofenac on the knee and a second topical medication on the same knee; Use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant

Dosage: SOLUTION;TOPICAL